Background: The concept of borderline resectability has not yet been introduced for extrahepatic cholangiocarcinoma (ECC). In this study, the surgical results of ECC patients were analyzed to clarify the implications of surgery for distal ECC with portal vein (PV) invasion as a preliminary step for the introduction of the concept of borderline resectability.
Methods: The clinicopathological data of 129 patients who had undergone pancreatoduodenectomy of distal ECC were reviewed retrospectively. Combined PV resection was performed in 10 patients. The clinicopathological variables were evaluated using univariate and multivariate analyses.
Results: Pathological PV invasion was observed in eight of the 129 patients. The survival rates of patients with PV invasion were significantly poorer than those of patients without PV invasion: 3 and 5 years after surgery, 17% and 0% versus 50% and 39% (P < 0.001), respectively. Presence of pancreatic or PV invasion, tumor progression, nodal status, and residual tumor were significant prognostic factors on univariate analysis. On multivariate analysis, PV invasion was the only significant independent predictive factor of a poor prognosis.
Conclusions: PV invasion of distal ECC should be regarded as indicating borderline resectability.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jhbp.198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: A successful case of targeted immunotherapy for locally advanced pancreatic cancer under non-surgical conditions.
Front Immunol
January 2025
Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Introduction: Locally advanced pancreatic cancer (LAPC) is a borderline unresectable malignancy that presents significant treatment challenges. The management of LAPC remains a complex issue, particularly in patients who are not eligible for surgical resection.
Case: Here, we report the case of a 60-year-old woman diagnosed with LAPC through pathological biopsy who subsequently underwent targeted immunotherapy following the failure of a gemcitabine, oxaliplatin, and S-1 (G&S) chemotherapy regimen.
Single-Site Endoscopic Surgery for Soft Tissue Lesions: An Innovative Technique.
Cureus
December 2024
Department of Pediatric Surgery and Vascular Anomalies, Xi'an International Medical Center Hospital, Xi'an, CHN.
Purpose We aimed to report an innovative single-site endoscopic surgery for soft tissue lesions performed at our center. Methods All patients who underwent soft tissue surgery were reviewed. All consecutive patients who underwent single-site endoscopic surgery between September 2019 and March 2024 were included in the study.
View Article and Find Full Text PDFReply to letter to editor by yinfang Wu, MM about our manuscript, "A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable or borderline resectable pancreatic cancer".
Surgery
January 2025
Department of Surgery, Osaka International Cancer Institute, Osaka, Japan.
Dose-Escalated SBRT for Borderline and Locally Advanced Pancreatic Cancer: Resectability Rate and Pathological Results of a Multicenter Prospective Study.
Cancers (Basel)
January 2025
Canarian Insitute for Cancer Research, 380204 San Cristobal de La Laguna, Spain.
Objective: We demonstrated for the first time the safety and feasibility of escalating up to 55 Gy/11 Gy/fr/5fr in borderline (BRPC)/unresectable locally advanced pancreatic cancer (LAPC), using the standard LINAC platform. The aim of the present study is to assess for the first time the impact of this high-dose neoadjuvant stereotactic ablative radiotherapy (SABRT) protocol on tumor resectability and pathological responses.
Materials/methods: From June 2017 to December 2022, patients with BRPC/LAPC were treated with neoadjuvant chemotherapy (ChT) and SABRT-escalated doses of SIB at 45 Gy, 50 Gy, and up to 55 Gy (BED ≥ 100).
3D modeling to predict vascular involvement in resectable pancreatic adenocarcinoma.
Heliyon
January 2025
Department of General Surgery, Fribourg Cantonal Hospital, 1700, Fribourg, Switzerland.
Background: Current management of patients with borderline resectable pancreatic adenocarcinoma (BR-PDAC) depends on the degree of involvement of the major arterial and venous structures. The aim of this study was to evaluate 3D segmentation and printing to predict tumor size and vascular involvement of BR-PDAC to improve pre-operative planning of vascular resection and better select patients for neoadjuvant therapy.
Methods: We retrospectively evaluated 16 patients with BR-PDAC near vascular structures who underwent pancreatoduodenectomy (PD) with or without vascular resection between 2015 and 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!